Amdinocillin

Summary

Amdinocillin (CHEMBL530) is an approved small molecule (ATC J01CA11); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA11
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 325.4 Da · C15H23N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL530
Name	Amdinocillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	36273
ATC	J01CA11
Molecular formula	C15H23N3O3S
Molecular weight	325.4
InChIKey	BWWVAEOLVKTZFQ-NTZNESFSSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Also known as: Amdinocillin, Coactin, FL 1060, FL-1060, Mecilinam, Mecillinam, Selecidin, Selexidin, AMDINOCILLIN, SID144205762, SID170465354, amdinocillin

Patent coverage: 1,202 distinct patent families (4,174 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01849926	PHASE4	COMPLETED	Ibuprofen Versus Mecillinam for Uncomplicated Cystitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).